Success Metrics

Clinical Success Rate
80.0%

Based on 8 completed trials

Completion Rate
80%(8/10)
Active Trials
0(0%)
Results Posted
38%(3 trials)
Terminated
2(20%)

Phase Distribution

Ph phase_1
7
70%
Ph phase_2
3
30%

Phase Distribution

7

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
7(70.0%)
Phase 2Efficacy & side effects
3(30.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

8 of 10 finished

Non-Completion Rate

20.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(8)
Terminated(2)

Detailed Status

Completed8
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
80.0%
Most Advanced
Phase 2

Trials by Phase

Phase 17 (70.0%)
Phase 23 (30.0%)

Trials by Status

completed880%
terminated220%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_2

Study to Evaluate a HIV Drug for the Treatment of HIV Infection

NCT01803074
terminatedphase_2

Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults

NCT02415595
terminatedphase_2

Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults

NCT02386098
completedphase_1

Study on Effects of BMS-955176 on the Pharmacokinetics of Probe Substrates

NCT02578277
completedphase_1

Taste Properties of HIV Inhibitor

NCT02608918
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT01803074Phase 2

Study to Evaluate a HIV Drug for the Treatment of HIV Infection

Completed
NCT02415595Phase 2

Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults

Terminated
NCT02386098Phase 2

Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults

Terminated
NCT02578277Phase 1

Study on Effects of BMS-955176 on the Pharmacokinetics of Probe Substrates

Completed
NCT02608918Phase 1

Taste Properties of HIV Inhibitor

Completed
NCT02206711Phase 1

Study of the Absorption, Metabolism, and Route of Elimination of a Novel Class of Anti-HIV 1 Drugs (BMS-955176) in Humans.

Completed
NCT02157467Phase 1

Study of Combined Oral Contraceptive Effects in Female Subjects

Completed
NCT02095886Phase 1

Relative Bioavailability Study With BMS-955176

Completed
NCT02273947Phase 1

Food Effect Study With BMS-955176

Completed
NCT02715479Phase 1

A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10